Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab Vedotin + RC98 in HER2-expressing Gastric Cancer
NCT05514158Phase 1Recruiting
- Sponsor
- RemeGen
- Start
- Sep 2022
- Primary completion
- May 2024
- Modality
- IgG Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rc98 in gastric cancer (GC) and gastroesophageal junction adenocarcinoma, sponsored by RemeGen. Primary endpoints: Dose Limiting Toxicity at 28 days and Incidence and Severity of Adverse Events. Started Sep 2022; status: recruiting.
02
Drugs
rc98
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT05514158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05514158.